Tag: transparency
The Epstein Diversion: Trump's Grand Jury Head Fake

The Epstein Diversion: Trump's Grand Jury Head Fake

Faced with a firestorm over his administration's broken promise to provide “full transparency” on all the materials related to Jeffrey Epstein—compounded by the Wall Street Journal’s revelation of a vulgar letter he contributed to a notebook compiled for Epstein’s 50th birthday in 2003—Donald Trump has now agreed to make public the entirety of the Epstein file.

Just kidding.

Trump, in fact, is attempting a cynical and hollow gambit that shouldn’t fool even the most credulous of his supporters.

He directed Attorney General Pam Bondi to seek the release of “all pertinent grand jury testimony” from the Ghislaine Maxwell prosecution, tried in 2021 after Epstein committed suicide while awaiting trial. He is attempting to position himself as a pro-transparency advocate but is content to leave the decision to the court.

The Justice Department motion—which the deputy attorney general signed last week and which Bondi then championed on Fox News—promises the faithful that Trump is “demanding full transparency.” In reality, it’s a ham-handed diversion tactic, carefully designed to reveal nothing at all.

There are two independent and fatal defects in the DOJ motion that ensure it’s a head fake.

First, the motion has no chance of producing what everyone is waiting to see. At Trump’s behest, Blanche and company submitted a short filing to the Southern District of New York court overseeing Maxwell’s case, requesting the release of all “pertinent” grand jury materials. (“Pertinent” is itself a tell—the motion is hedged and lawyered; that word is not part of Trump’s normal working vocabulary.)

Crucially, the Maxwell prosecution had nothing to do with Epstein’s sleazy friends or alleged clients. That’s not how the indictment was structured. The SDNY team, led by Maurene Comey (Jim Comey’s daughter, whom Bondi fired last week), brought the case more than a decade after the Wall Street Journal reported the DOJ had reviewed the Epstein materials. Their clear focus was Maxwell and Epstein himself.

The supporting players in the indictment were Epstein’s associates, led by Maxwell, who helped him locate, groom, and abuse young girls—along with the victims themselves. The charge required only that some commercial sex act was contemplated or intended. The sex acts referenced in the indictment involved Epstein alone.

What Comey successfully moved to keep under seal were the grand jury materials that might be needed if the government were to bring a new case against Maxwell—either the one count on which she wasn’t convicted or in the (highly unlikely) event her convictions are reversed on appeal.

That’s why the grand jury materials Trump now says he wants disclosed are completely unrelated to the information about Epstein’s circle that MAGA is clamoring for—starting with the infamous 50th birthday notebook and Trump’s own ribald contribution.

Ah yes, the notebook—the term that has become shorthand for the real object of public fascination. According to the Wall Street Journal, DOJ officials reviewed a small, handwritten book allegedly recovered during the FBI’s 2006 investigation into Epstein—three years before his sweetheart plea deal in Florida.

That probe, which ran from 2003 to 2006, generated a reported 300 gigabytes of material—equivalent to approximately 150 million pages.

There is likely additional material related to Trump in that vast trove. We know, for example, that he flew on Epstein’s private plane at least seven times.

That’s not to say there is any information tying him to the actual sex trafficking.

Which is exactly what makes it so strange—and so ill-advised—that Trump has opted to go all in on a claim that is near certain to collapse: that the Wall Street Journal fabricated the story about the birthday letter. (My Substack from yesterday deals at length with the misguidedness of that suit.)

The material MAGA is clamoring for—names, logs, financial records, and whatever “wonderful secrets” (as Trump put it in the sign-off to his letter) Epstein’s trove might contain—is not part of the Maxwell grand jury file.

The motion poses no prospect of giving the chunk of Trump’s base deeply concerned about Epstein’s conduct what it is demanding.

More cynically still, Trump has structured things so he can claim he did his best—but that the court simply wouldn’t let him satisfy the MAGA faithful. His stance of leaving it all up to the court’s decision is a bad joke, given that he has treated the judiciary with more contempt and defiance than any president in history.

In fact, this is part of a broader strategy: appear to want the court to grant the motion while actually expecting—and being perfectly content with—the opposite. If the court rejects the request, Trump can throw up his hands and tell the base, “See? I tried.”

That leads to the second obvious problem with the Trump/Bondi gambit.

Even if the SDNY court were inclined to entertain the motion—which it almost certainly is not—Rule 6(e) of the Federal Rules of Criminal Procedure presents an imposing barrier.

Rule 6(e) governs the secrecy of grand jury materials. It strongly disfavors unsealing and provides six narrow exceptions for when disclosure is allowed. None of them includes “public interest,” “public outcry,” or “political meltdown.” You can’t pierce grand jury secrecy just because the public is in a frenzy or a president is under fire.

In its filing, DOJ cites a single case in which a court hinted the six exceptions might not be exhaustive. But that case involved a matter of keen historical interest—and the court expressly distinguished that from political or public interest of the sort DOJ now appeals to. Even then, the court declined to unseal the materials based on the extra-statutory argument.

In sum, DOJ’s precedent provides scant basis for unsealing the grand jury record—and the rules themselves provide none.

And that, of course, is the point. Trump and his team know the motion is a loser. They know it won’t result in disclosures. They’re counting on that.

The goal isn’t to win—it’s to pretend to try. Trump wants to tell his base he pulled every lever to get to the bottom of the Epstein affair, only to be thwarted by the Deep State, the Swamp, the corrupt judiciary, or whichever villain suits this week’s narrative.

The problem? MAGA isn’t demanding transparency in the Maxwell prosecution. They want names. They want proof of the global pedophilia ring they believe was run by Epstein and his powerful friends. They want the notebook. None of that is in the SDNY grand jury file.

This is Trump’s gambit in a nutshell: pretend DOJ is declassifying the “good stuff,” knowing it isn’t; wait for judicial rejection; and reframe himself as the truth-teller blocked by the forces of darkness.

Then, when the well-intended gesture fails, Trump can pivot: “I tried. Enough is enough. Now let’s move on.”

It’s a flimsy con from a lifelong con artist. And given the intensity of MAGA’s obsession with Epstein’s secrets, it’s unlikely to do anything to stem the escalating furor.

Harry Litman is a former United States Attorney and the executive producer and host of the Talking Feds podcast. He has taught law at UCLA, Berkeley, and Georgetown and served as a deputy assistant attorney general in the Clinton Administration. Please consider subscribing to Talking Feds on Substack.

Reprinted with permission from Substack.

Abandoning 'Transparency,' RFK Jr Initiates Shady Drug Approval Scheme

Abandoning 'Transparency,' RFK Jr Initiates Shady Drug Approval Scheme

HHS Secretary Robert F. Kennedy Jr. at first promised “radical transparency” at all agencies within his department. Then he fired almost all the freedom of information staff at the Centers for Disease Control and Prevention, the Food and Drug Administration and the National Institutes of Health; cancelled meetings of FDA and CDC advisory committees that review vaccines and vaccine policies; and held meetings of his Make America Healthy Again Commission behind closed doors.

Marty Makary, the new head of FDA, boldly promised to purge all physicians and scientists on the agency’s 49 outside advisory committees with ties to private industry. The move, he said, heralded a new era where advisory committees with a diversity of opinions would offer advice free from industry influence.

Then, on Tueday, he announced a new program that will set up internal committees to rapidly approve experimental drugs within two months of receiving a company’s application. Given the short time frame, this will effectively bypass the agency’s advisory committee process.

The usual FDA review process often includes holding advisory committee meetings, especially when the clinical trial evidence on safety and efficacy for an experimental therapy is borderline. The review usually takes anywhere from ten months to a year.

As for speeding up the process, the agency already offers priority review vouchers for new drugs that meet unmet medical needs, treat rare diseases or are considered a breakthrough therapy. Those vouchers can then be used on any future drug application even if it doesn’t meet any of those criteria. It can also be sold to another company seeking rapid approval of a drug that isn’t critical.


Some products receiving priority reviews by agency scientists also benefit from the FDA’s accelerated approval process, where approvals are based an improvement in surrogate markers — biomarkers like elevated amyloid plaques in Alzheimer’s patients or tumor shrinkage in cancer patients that aren’t necessarily associated with a better outcomes when the final results of those clinical trials are in (which sometimes are never submitted because the drug companies fail to complete the trials).

What’s new here?

The new program layers on an immediate rapid review to any company developing a new drug or device that meets one of four criteria: Does it address a health crisis; deliver an innovative cure; meet an unmet public health need; or increase the nation’s domestic drug manufacturing capacity?

The first three criteria are so vague as to be essentially meaningless. Virtually every drug and device company claims their new products are innovative and address unmet needs, even when they’re the sixth drug in a class that treats an already well-managed condition.

As Aaron Kesselheim, a professor of medicine and member of the Center for Bioethics at Harvard Medical School, told STAT News yesterday: “It sounds like a way of giving out political favors rather than actually meaningfully changing or enhancing the regulatory process.”

The internal process for making decisions after awarding these new priority reviews will be equally problematic. Makary, a surgical oncologist, plans to convene experts from various FDA offices for a “1-day” team review that he compared to the tumor boards hospitals use when faced with a critically ill cancer patient. “This voucher harnesses that model to deliver timely decisions for drug developers,” he said in his statement.

That ignores the fact that many new drugs to treat chronic conditions like dementia, cancer, autoimmune disorders, and rare genetic diseases are often barely effective. They often have troubling safety profiles requiring careful weighing of minimal rewards against serious risks. These are the areas where FDA reviewers are most in need of advice from outside experts through the advisory committee process.

Prior to advisory committee meetings, the FDA publishes much of the data submitted by the companies seeking a new drug approval. It posts on its website its own analysis as well as the companies’ presentations of the data, which the public can review prior to the meeting. The meeting itself — often stretching over several days — are open sessions where the advisors hear from clinicians who treat patients suffering from the disease as well as consumer and safety advocates who urge the agency to give careful consideration to the risk-reward ratio.

Will these one-day “tumor board”-like sessions be open to the public? Will internal documents be published? Will they hear from interested parties?

If the goal of the new program is to shorten the FDA’s review time, the agency needn’t come up with another work around. The simplest solution is to hire additional staff.

Instead, HHS at the urging of Elon Musk’s DOGE and the Russell Vought’s Office of Management and Budget announced the FDA will be laying off 3,500 of its 19,000 staffers, exempting for the time being new product reviewers. Why not use the savings to hire more internal reviewers? That’s the surest path to shortening review times.

This new program also ignores the fact that the FDA is already heavily dependent on industry user fees to fund its review staff, which is the biggest conflict of interest at the agency. Why don’t Kennedy and Makary go to Vought and his boss in the Oval Office to demand they include more taxpayer funding for FDA reviewers instead of giving more tax breaks to the wealthy and large corporations?

Reprinted with permission from Gooz News.

Still Waiting For Newspaper Editorials Demanding The Trump Foundation Be Shut Down

Still Waiting For Newspaper Editorials Demanding The Trump Foundation Be Shut Down

Published with permission from Media Matters for America.

Adding to a cavalcade of campaign condemnations, a string of major newspaper editorial boards in recent weeks stepped forward to announce that, in the name of avoiding even the appearance of a conflict of interest, Bill and Hillary Clinton needed to shut down their successful Clinton Foundation.

Conceding that recent news reports hadn’t proven any actual wrongdoing or lawbreaking with the foundation and its connection the State Department when Clinton was secretary of state, editorials from Washington PostBoston Globe, and USA Today, among others, were nonetheless adamant: Shut it down.

Columnists at SlateNew York and The Wall Street Journal also jumped in, as did an array of TV talkers anxious to add their voices to the media choir demanding a global charity be shut down because the optics didn’t look quite right. And several outlets insisted that waiting until after the election for foundation action wasn’t “good enough.”

Everyone, it seemed, was in heated agreement.

  • “Even if they’ve done nothing illegal, the foundation will always look too much like a conflict of interest for comfort.” (Boston Globe)
  • “[T]he only way to eliminate the odor surrounding the foundation is to wind it down and put it in mothballs.”  (USA Today)
  • “Impressions such as these are corrosive to national institutions.” (Washington Post)

On and on the editorials went, patiently explaining to Clinton what she needed to do to eliminate budding concerns within the Beltway press; how she had to shutter her landmark charity in order to please the optics police.

Reading the proclamations, it was clear to readers that even the appearance of impropriety when it comes to politicians and charitable foundations must be met with swift, pro-active and even drastic action.

So what explains the deafening editorial board silence about the Donald J. Trump Foundation in the wake of the shocking news report that in 2013 it sent an illegal $25,000 donation to a political group supporting Florida’s attorney general, Pam Bondi? At a time, her office was considering opening a fraud investigation into Trump University and widespread allegations the company had cheated students. After the group supporting Bondi received the large Trump check, which she reportedly personally solicited, her office announced it wasn’t going to investigate Trump University.

Where’s the collective demand that the Trump Foundation be shut down because of conflicts?

Not only does the payoff reek of a quid pro quo arrangement, but the generous Foundation donation was also against the law because as a registered non-profit organization, the Trump Foundation isn’t allowed to make political contributions. It appears the Foundation may have taken steps to cover up the donation by by listing the recipient of the funds as a Kansas-based charity in tax forms, according to the Washington Post report. After the $25,000 check was brought to light earlier this year, Trump’s organization paid a $2,500 fine to the IRS.

Given the hyper attention paid to the Clinton Foundation, and the relentless media search for wrongdoing, the Trump revelations are astounding: They seem to represent precisely the type of naked misdeed the press has been trying to uncover with regards to Clinton. But instead, the foundation’s wrongdoing is attached to the Republican nominee and the campaign press reaction has been muted, to say the least.

On the Sunday morning talk shows this week, the story was occasionally referenced by guests, but CBS’s Face The Nation host John Dickerson was the only host to bring up the Trump/Bondi controversy.

Meanwhile, according to a search of CNN transcripts via Nexis, “Trump Foundation” was mentioned in one on-air report on the all-news channel between Monday, August 29, through Monday, September 5. By contrast, “Clinton Foundation” was mentioned in dozens of CNN reports during that same time period.

Keep in mind, the constant media churning about Clinton “optics” revolve around a global charity that represents a textbook example of how to build a modern-day foundation for giving. “If Hillary Clinton wasn’t running for president, the Clinton Foundation would be seen as one of the great humanitarian charities of our generation,” Daniel Borochoff of Charity Watch recently told CNN. (The foundation receives exceptional marks from watchdog organizations.)

The Clinton Foundation’s sterling reputation has now been tarnished, in part because the press has decided to go all in with the GOP’s smear campaign against the charity. It’s decided to overhype trivial revelations about Foundation contacts and meetings that took place years ago.

But when the Trump Foundation is found to have illegally donated to a state attorney general who was contemplating fraud charges against a Trump company? Suddenly the referees on newspaper editorial boards fall silent.

Photo: Republican presidential nominee Donald Trump stands on stage during a campaign town hall meeting in Virginia Beach, Virginia, U.S., September 6, 2016.  REUTERS/Mike Segar

Report: Obama Administration Worse Than Ever On Freedom Of Information Requests

Report: Obama Administration Worse Than Ever On Freedom Of Information Requests

By Arit John, Bloomberg News (TNS)

The Obama administration continued its less than stellar transparency record in 2014, breaking the previous year’s record for denying and censoring requests under the Freedom of Information Act, according to a new analysis of the administration’s FOIA data by the Associated Press.

The report comes in the midst of Sunshine Week, which raises awareness of open government issues like compliance with the Freedom of Information Act. The White House has already faced some criticism this week for formalizing a rule from the Bush administration that exempts the White House’s Office of Administration from FOIA requests.

According to the AP, the government “took longer to turn over files when it provided any, said more regularly that it couldn’t find documents, and refused a record number of times to turn over files quickly that might be especially newsworthy.” A third of the government’s decisions to withhold documents violated the Freedom of Information Act, the news organization said.

This is the second report this week to shine a light on the government’s transparency under FOIA. A Tuesday report from the Center for Effective Government, an open government advocacy group, analyzed 15 major agencies and found that most received unsatisfactory marks when it comes to processing requests, maintaining its disclosure rules, and updating its FOIA websites.

The State Department, currently in the news over former Secretary of State Hillary Clinton’s exclusive use of a private e-mail account, scored significantly worse than any other agency. It only processed 23 percent of all requests and took, on average, 540 days to fill simple FOIA requests; the law dictates that it should take 20 days.

The Obama administration — often mocked for its promise that it would be the most transparent administration in history — said that in 91 percent of cases the government released all or part of the documents requested. “We actually do have a lot to brag about when it comes to our responsiveness to Freedom of Information Act requests,” White House press secretary Josh Earnest said.

But the AP said the 91 percent figure doesn’t include instances where the document was lost, when the requester couldn’t or wouldn’t pay for copies, or when the document request was “determined to be improper under the law,” and is lower than any other year Obama has been in office.

Photo: President Barack Obama signs the Department of Homeland Security funding bill in the Oval Office of the White House on Wednesday, March 4, 2015, in Washington, D.C. (Olivier Douliery/Abaca Press/TNS)

Shop our Store

Headlines

Editor's Blog

Corona Virus

Trending

World